Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Cost of Revenue (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Cost of Revenue for 13 consecutive years, with $122.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 1.81% year-over-year to $122.9 million, compared with a TTM value of $468.7 million through Dec 2025, up 4.02%, and an annual FY2025 reading of $468.7 million, up 4.02% over the prior year.
  • Cost of Revenue was $122.9 million for Q4 2025 at Tandem Diabetes Care, up from $115.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $125.2 million in Q4 2024 and bottomed at $67.8 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $100.7 million, with a median of $99.2 million recorded in 2022.
  • The sharpest move saw Cost of Revenue skyrocketed 45.29% in 2021, then decreased 4.25% in 2023.
  • Year by year, Cost of Revenue stood at $96.3 million in 2021, then increased by 9.05% to $105.0 million in 2022, then decreased by 1.41% to $103.5 million in 2023, then increased by 20.96% to $125.2 million in 2024, then fell by 1.81% to $122.9 million in 2025.
  • Business Quant data shows Cost of Revenue for TNDM at $122.9 million in Q4 2025, $115.0 million in Q3 2025, and $114.8 million in Q2 2025.